Taha Dina E, Kabel Ahmed M, Yassin Ahmed I, Abdin Amany A
Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, 31527, Egypt.
Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, 31527, Egypt.
Eur J Pharmacol. 2025 Sep 5;1002:177875. doi: 10.1016/j.ejphar.2025.177875. Epub 2025 Jun 23.
Alzheimer's disease (AD) is a pervasive neurodegenerative disorder. Despite extensive research, its multifactorial etiology remains complex and not fully understood. The present study was performed to investigate the potential ameliorative effect of febuxostat and donepezil each alone or in combination on scopolamine-induced AD in male Wistar rats via targeting Thioredoxin-interacting protein (TXNIP)/NOD-like receptor protein-3 (NLRP3) inflammasome pathway.
In a rat model of scopolamine-induced AD, the changes in the behavioral tests, biochemical parameters, and the histopathological picture in the hippocampal and cerebral tissues were assessed.
Administration of either donepezil or febuxostat to scopolamine-induced AD rats significantly improved the behavioral changes, decremented TXNIP levels with amelioration of the neuroinflammation by decreased NLRP3, and IL-1β levels, restoration of the oxidant/antioxidant balance and inhibition of apoptosis by increasing expression of anti-apoptotic protein Bcl-2 with restoration of ACh levels. Notably, only febuxostat causes normalization of fasting blood glucose levels. These changes were positively reflected on the histopathological picture and scoring in both tissues. These beneficial effects were significantly more evidenced in rats treated with donepezil/febuxostat combination relative to monotherapy by either donepezil or febuxostat. The impact of the tested parameters in the disease outcome was evidenced by their significant correlation and moreover the causality by the significant regression, shedding light particularly for the glycemic state and the neuroinflammatory reactions.
These elaborated data signified the neuroprotective effect of febuxostat and indicated that donepezil/febuxostat combination strengthened each other as they act by different mechanisms to counteract AD.
阿尔茨海默病(AD)是一种普遍存在的神经退行性疾病。尽管进行了广泛研究,但其多因素病因仍很复杂且尚未完全了解。本研究旨在通过靶向硫氧还蛋白相互作用蛋白(TXNIP)/NOD样受体蛋白3(NLRP3)炎性小体途径,研究非布司他和多奈哌齐单独或联合使用对东莨菪碱诱导的雄性Wistar大鼠AD的潜在改善作用。
在东莨菪碱诱导的AD大鼠模型中,评估行为测试、生化参数以及海马和脑组织的组织病理学图像的变化。
给东莨菪碱诱导的AD大鼠施用多奈哌齐或非布司他均显著改善了行为变化,降低了TXNIP水平,通过降低NLRP3和IL-1β水平减轻了神经炎症,恢复了氧化/抗氧化平衡,并通过增加抗凋亡蛋白Bcl-2的表达抑制了细胞凋亡,同时恢复了乙酰胆碱水平。值得注意的是,只有非布司他使空腹血糖水平恢复正常。这些变化在两个组织的组织病理学图像和评分上得到了积极反映。与多奈哌齐或非布司他单药治疗相比,多奈哌齐/非布司他联合治疗的大鼠中这些有益作用更为明显。测试参数与疾病结果之间的显著相关性以及显著回归所显示的因果关系,证明了它们对疾病结局的影响,特别是对血糖状态和神经炎症反应的影响。
这些详细数据表明了非布司他的神经保护作用,并表明多奈哌齐/非布司他联合使用时通过不同机制发挥作用以对抗AD,二者相互增强疗效。